Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]
Discontinued
Reference number: GID-TA10531
Following on from information provided to NICE by the company in June 2021, the appraisal of Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.